logo
logo
AI

Discover the World’s Fastest Business Insights

Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.

Tavotek Biotherapeutics Announces Completion Of Round B Financing With $35 Million

Tavotek Biotherapeutics Announces Completion Of Round B Financing With $35 Million

11/19/21, 7:00 PM
Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing will be used to accelerate the Phase 1 clinical development of several antibody drugs to start in early 2022. The upcoming antibody drugs were developed by the company based on its TavoPrecise antibody platform for various immune-related disorders

Company Info

Company
Tavotek
Additional Info
Tavotek is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing medicines for patients suffering from debilitating diseases with significant unmet medical needs. Tavotek has a rich pipeline of product candidates at various stages of development for cancer, autoimmune conditions, and inflammatory diseases. For more information, please visit www.tavotek.com.
G2 High Performer Badge

Never Miss an Opportunity: Your #1 Sales Intelligence Tool

Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.